Compared to other cancers, pancreatic cancer is relatively rare. But it is the third leading cause of cancer death in the United States. Only about 8.5% of patients with pancreatic cancer are alive five years after their diagnosis. This one of the lowest survival rates for any kind of cancer. What makes pancreatic cancer so deadly?
Pancreatic Cancer News
In less than three years, HCI researchers have taken an idea from concept to lab to clinical evaluation. Conan Kinsey, MD, PhD, and Martin McMahon, PhD, combined two drugs that had not been used in combination before to treat pancreatic tumors. The results were promising and they were able to move from the lab to clinical trial quickly. A clinical trial to test the safety and effect of this drug combination in pancreatic cancer is now underway at HCI and planned at other sites around the United States.
Neal Blair will be 80 in a few weeks. He recently retired from his work as a political consultant. Perhaps that doesn’t seem so remarkable. But in May 2016, Neal was diagnosed with pancreas cancer. Two and a half years later, he is NED—his follow-up tests show no evidence of disease. And that is remarkable.
By unraveling the link between obesity and gastrointestinal cancers, researchers hope to develop effective treatments and strategies for lowering cancer risk. A team of scientists at Huntsman Cancer Institute published a wide review of findings on the biological links between obesity and gastrointestinal cancers. They also examined studies on how diet, exercise, and other weight-related interventions may help reverse this connection.
Immunotherapy has shown to be an effective treatment for several types of cancer. Is pancreatic cancer one of them? Ignacio Garrido-Laguna, MD, PhD, answers that question during Pancreatic Cancer Awareness Month.